Table 1.
Patient baseline characteristics (number = 819).
| Characteristic | Number | % |
|---|---|---|
| Age at diagnosis | ||
| < 50 | 290 | 35.4 |
| > 50 | 529 | 64.6 |
| T stage | ||
| T1 | 613 | 74.8 |
| T2 | 195 | 23.8 |
| T3 | 11 | 1.4 |
| Number of positive nodes | ||
| 0 | 586 | 71.6 |
| 1-3 | 219 | 26.7 |
| > 4 | 10 | 1.2 |
| No nodes sampled | 4 | 0.5 |
| Grade | ||
| 1 | 84 | 10.3 |
| 2 | 431 | 52.6 |
| 3 | 300 | 36.6 |
| Unknown | 4 | 0.5 |
| ER or PR positive | 656 | 80.1 |
| HER2 positive | 109 | 13.3 |
| LVI present | 137 | 16.7 |
| Hormonal therapy received | 553 | 67.5 |
| Chemotherapy received | 389 | 47.5 |
| Trastuzumab therapy received (if HER2 positive, Number = 108) | 28 | 25.9 |
| Margins | ||
| Close or positive | 27 | 3.3 |
| Negative | 791 | 96.6 |
| Unknown | 1 | 0.1 |
| Constructed subtype | ||
| HR+/HER2+ | 574 | 70 |
| HR+HER2+ | 57 | 7 |
| HR-/HER2+ | 51 | 6.2 |
| HR-/HER2- | 94 | 11.5 |
| Unknown | 43 | 5.3 |
ER, estrogen receptor; HER2, human epidermal growth receptor 2; LVI, lymphovascular space invasion; PR, progesterone receptor.